# US 2026/0035349 A1 · 3,4-alkoxy Substituted Phenethyl Lactam Compound, Preparation Method therefor, and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0035349 A1
- Document ID: US20260035349A1
- Status: Published application
- Kind: A1
- Application number: 19/277,665
- Filed: 2025-07-23
- Published: 2026-02-05
- Earliest claimed: 2024-08-02
- Assignees: Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.; Institute of Materia Medica, Chinese Academy of Medical Sciences
- Applicants: Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.; Institute of Materia Medica Chinese Academy of Medical Sciences
- Inventors: Chen Wang; Xiang Zhang; Fei Xiao; Yonghong Liao; Xu Yang; Min Dong; Dali Yin; Xiaomao Xu; Qiong Xiao; Yulin Tian; Hong Yang
- Web page: https://patentgrep.com/patent/US20260035349A1

## CPC

- C07D 237/14: Oxygen atoms
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- C07D 207/26: 2-Pyrrolidones
- C07D 211/76: attached in position 2 or 6
- C07D 211/94: Oxygen atom, e.g. piperidine N-oxide
- C07D 213/64: attached in position 2 or 6
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 239/36: as doubly bound oxygen atom or as unsubstituted hydroxy radical
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure pertains to the technical field of pharmaceutics, and relates to a 3,4-alkoxy substituted phenethyl lactam compound as an enzyme inhibitor of phosphodiesterases, a preparation method therefor, and pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by general formula (I), a preparation method therefor, and use thereof in a medicament for preventing and/or treating a phosphodiesterase-associated disease.

## Claims

### Claim 1

A compound, or an isomer, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of formula (I):
wherein:
ring A is selected from the group consisting of a 5-7 membered lactam ring, and is independently and optionally substituted with R1 and R2;
R1 and R2 are identical or different and are each independently and optionally selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, C3-C6 cycloalkyl, —OR3, and —(CH2)zCHF2;
the R3 described above is selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, and C3-C6 cycloalkyl;
i is selected from the group consisting of 0, 1, 2, 3, and 4;
z is selected from the group consisting of 0, 1, 2, and 3.

### Claim 2 (depends on 1)

The compound according to claim 1, or the isomer, or the pharmaceutically acceptable salt thereof:
wherein the compound, or the isomer, or the pharmaceutically acceptable salt thereof is independently and optionally substituted with R1 and R2, wherein R1 and R2 are identical or different and are each independently and optionally selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, C3-C6 cycloalkyl, —OR3, and —(CH2)zCHF2; the R3 described above is selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, and C3-C6 cycloalkyl; i is selected from the group consisting of 0, 1, 2, 3, and 4; z is selected from the group consisting of 0, 1, 2, and 3; n is selected from the group consisting of 1, 2, and 3.

### Claim 3 (depends on 2)

The compound according to claim 2, or the isomer, or the pharmaceutically acceptable salt thereof, wherein 2-(cyclopropylmethoxy)-1-(difluoromethoxy)-4-phenethyl is located meta or para to the carbonyl group on the 5-7 membered lactam ring substituted with R1 and R2, wherein the R1 and R2 on the lactam ring are identical or different and are each independently and optionally selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, C3-C6 cycloalkyl, —OR3, and —(CH2)zCHF2; the R3 described above is selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, and C3-C6 cycloalkyl; i is selected from the group consisting of 0, 1, 2, 3, and 4; z is selected from the group consisting of 0, 1, 2, and 3; n is selected from the group consisting of 1, 2, and 3.

### Claim 4 (depends on 1)

The compound according to claim 1, or the isomer, or the pharmaceutically acceptable salt thereof, wherein when ring A is selected from the group consisting of 2-pyridone, 2-pyrazinone, 2-pyrimidinone, 3-pyridazinone, 4-pyrimidinone, and triazinone, ring A is independently and optionally substituted with R1 and R2, wherein R1 and R2 are independently and optionally selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, C3-C6 cycloalkyl, —OR3, and —(CH2)zCHF2; the R3 described above is selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, and C3-C6 cycloalkyl; i is selected from the group consisting of 0, 1, 2, and 3; z is selected from the group consisting of 0, 1, 2, and 3.

### Claim 5 (depends on 4)

The compound according to claim 4, or the isomer, or the pharmaceutically acceptable salt thereof, wherein 2-(cyclopropylmethoxy)-1-(difluoromethoxy)-4-phenethyl is located meta or para to the carbonyl group on the 5-6 membered lactam ring substituted with R1 and R2, wherein R1 and R2 are independently and optionally selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, C3-C6 cycloalkyl, —OR3, and —(CH2)zCHF2; the R3 described above is selected from the group consisting of hydrogen, C1-C4 linear or branched alkyl, C1-C4 heteroalkyl, and C3-C6 cycloalkyl; i is selected from the group consisting of 0, 1, 2, and 3; z is selected from the group consisting of 0, 1, 2, and 3.

### Claim 6 (depends on 1)

The compound according to claim 1, or the isomer, or the pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of the following compounds:

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical combination, comprising an effective dose of the compound according to any one of claims 1-6, or the isomer, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

Use of the compound according to any one of claims 1-6, or the isomer, or the pharmaceutically acceptable salt thereof for preparing a phosphodiesterase inhibitor.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

Use of the compound according to any one of claims 1-6, or the isomer, or the pharmaceutically acceptable salt thereof for preparing a medicament for preventing and/or treating a phosphodiesterase-associated disease.
